Skip to main content

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.

Publication ,  Journal Article
Clamon, G; Herndon, J; Cooper, R; Chang, AY; Rosenman, J; Green, MR
Published in: J Clin Oncol
January 1999

PURPOSE: To determine whether the administration of carboplatin concurrently with radiation treatment improves survival in patients with inoperable stage III non-small-cell lung cancer. PATIENTS AND METHODS: Two hundred eighty-three patients with inoperable stage III non-small-cell lung cancer were entered onto a randomized trial by the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. Randomization was performed before initiation of any therapy. All patients received an induction chemotherapy program with vinblastine and cisplatin for 5 weeks, followed by 6,000 cGy of radiation therapy over 6 weeks. One hundred thirty-seven patients were randomized to this therapy regimen alone; 146 patients were randomized to receive carboplatin at 100 mg/m2/wk concurrent with the radiation therapy. RESULTS: The complete response was 18% with concurrent carboplatin versus 10% with radiotherapy alone (P = .101). There was no difference with respect to failure-free survival (10% with carboplatin and 9% with radiotherapy alone) or overall survival (13% with carboplatin and 10% with radiotherapy alone) at 4 years. In patients not receiving carboplatin, the relapse rate was 69% within the field of radiation and 53% in the boost volume. In patients receiving carboplatin, the relapse rate was 59% within the field of radiation and 43% in the boost volume. Patients with cancers more than 70 cm2 in size had significantly poorer survival (P = .01). CONCLUSION: Carboplatin at the dose and schedule used did not significantly impact on disease control or survival. The relapse rate within the chest remained more than 50%. More effective regimens will be required to impact on local disease control and survival.

Duke Scholars

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

January 1999

Volume

17

Issue

1

Start / End Page

4 / 11

Location

United States

Related Subject Headings

  • Vinblastine
  • Survival Rate
  • Radiation-Sensitizing Agents
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clamon, G., Herndon, J., Cooper, R., Chang, A. Y., Rosenman, J., & Green, M. R. (1999). Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol, 17(1), 4–11. https://doi.org/10.1200/JCO.1999.17.1.4
Clamon, G., J. Herndon, R. Cooper, A. Y. Chang, J. Rosenman, and M. R. Green. “Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.J Clin Oncol 17, no. 1 (January 1999): 4–11. https://doi.org/10.1200/JCO.1999.17.1.4.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

January 1999

Volume

17

Issue

1

Start / End Page

4 / 11

Location

United States

Related Subject Headings

  • Vinblastine
  • Survival Rate
  • Radiation-Sensitizing Agents
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Humans
  • Female